Wyszukaj badanie kliniczne
266 Wyniki
Badanie kliniczne z otwartą rekrutacją
= 
; Badanie kliniczne w toku
= 
; Terminated trial = 
; Ufundowane przez członka IRDiRC = 
; MISSING CONTENT = 
Krajowe badania kliniczne
SZWAJCARIA
Suisse Alémanique
ZÜRICH
Prospective Assessment of MRI for Morphological and Functional Imaging in the Thorax
Universitätsspital Zürich
Institut für diagnostische und interventionelle Radiologie
ZJEDNOCZONE KRÓLESTWO
Cambridgeshire
CAMBRIDGE
APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital
Addenbrookes Hospital
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
Sicherheit von Abatacept bei der Behandlung von interstitiellen Lungenerkrankungen (ILD) bei Patienten mit variablem Immundefekt (CVID) und ähnlichen Erkrankungen.
Institution: Information not provided - DE
NIEMCY
Nordrhein-Westfalen
KÖLN
BETTER-B: Eine internationale, multizentrische, randomisierte, kontrollierte Phase III-Studie zur Evaluation von Mirtazapin zur Linderung von Atemnot in Palliative Care
Universitätsklinikum Köln
Zentrum für Palliativmedizin
IRLANDIA
County Dublin
DUBLIN
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
University College Dublin
UCD School of Medicine
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
BETTER-B: Studio pragmatico internazionale, multicentrico, randomizzato e controllato sulla mirtazapina per alleviare la dispnea nelle cure palliative e di fine vita - IT
Institution: Information not provided - IT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
The TRISTARDS Trial - ThRombolysIS Therapy for ARDS: A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care Compared With SOC Alone, in Patients With ARDS Triggered by COVID-19 - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial (Phase 2) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Allgemeine Anästhesie und Intensivmedizin
AUSTRIA
WIEN
WIEN
EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study - AT
Allgemeines Krankenhaus der Stadt Wien
Intensivstation 13.i2
AUSTRIA
WIEN
WIEN
DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome) - AT
Allgemeines Krankenhaus der Stadt Wien
Intensivstation 13.i2
AUSTRIA
WIEN
WIEN
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
AUSTRIA
WIEN
WIEN
COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial (phase 2)
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für klinische Pharmakologie
AUSTRIA
WIEN
WIEN
Noninvasive Vagal Nerve Stimulation in Patients With COVID-19 and ARDS for the Reduction of Respiratory, Hemodynamic and Neuropsychiatric Complications
SMZ Süd - Kaiser-Franz-Josef-Spital
4. Medizinische Abteilung mit Infektions- und Tropenmedizin
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPALA-2: Un essai clinique randomisé, en double aveugle et contrôlé par placebo portant sur une solution de nébulisation de molgramostim inhalée une fois par jour chez des sujets adultes atteints de protéinose alvéolaire pulmonaire auto-immune - BE
Erasme Hospital - ULB
Service de Pneumologie
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Un essai en double aveugle, randomisé et contrôlé par placebo évaluant l'efficacité et l'innocuité du BI 1015550 sur 52 semaines chez des patients atteints de maladie pulmonaire interstitielle fibrosante progressive - BE
Erasme Hospital - ULB
Service de Pneumologie
KANADA
Ontario
TORONTO
A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury
Mount Sinai Hospital
FINLANDIA
Finland
TURKU
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI-
Turku University Hospital
Turku PET CENTRE
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR
FRANCJA
BRETAGNE
RENNES
SARCOLOWDOSE : Tomodensitométrie ultra-basse dose dans l'imagerie de la sarcoïdose thoracique
CHU de Rennes - Hôpital Pontchaillou
Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire
FRANCJA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
ProCoCo: Corticothérapie guidée par le dosage du procollagène 3 au cours des syndromes de détresse respiratoire aiguë persistants
CHU de Marseille - Hôpital Nord
Service de réanimation médicale détresses respiratoires - Infections sévères
NIEMCY
Baden-Württemberg
HEIDELBERG
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Thoraxklinik-Heidelberg gGmbH
Abteilung für Pneumologie und Beatmungsmedizin
NIEMCY
Bayern
GAUTING
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Asklepios-Fachkliniken München-Gauting
Klinik für Pneumologie
NIEMCY
Nordrhein-Westfalen
ESSEN
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Universitätsklinikum Essen
NIEMCY
Schleswig-Holstein
LÜBECK
IMPALA-X: Eine offene, nicht kontrollierte, multizentrische klinische Studie mit inhaliertem Molgramostim bei Autoimmunpatienten mit Lungenalveolarproteinose
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Medizinische Klinik III - Pneumologie
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio IPERPEEP - Pressione positiva di fine espirazione individualizzata guidata dal volume polmonare di fine espirazione nella sindrome da distress respiratorio acuto da moderata a grave.
Institution: Information not provided - IT
WŁOCHY
LAZIO
ROMA
Effetti della pressione positiva di fine espirazione con e senza sincronizzazione inspiratoria in presenza di sindrome da distress respiratorio da moderata a grave
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
U.O.C. Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
Pulmonary alveolar proteinosis GM-CSF inhalation efficacy trial in Japan
Institution: Information not provided - JP
JAPONIA
JAPAN
KUMAMOTO
ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
Saiseikai Kumamoto Hospital
Respiratory Medicine & Surgery
JAPONIA
JAPAN
KYOTO
ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
University Hospital, Kyoto Prefectural University of Medicine
Department of Anesthesiology
HOLANDIA
Noord-Holland
AMSTERDAM
IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC
Afdeling Neurologie
HISZPANIA
Cataluña
L'HOSPITALET DE LLOBREGAT
LORALAM-2020: Ensayo Clínco randomizado Fase-II para evaluar el efecto de Loratadina asociada a Rapamune en Linfagioleiomiomatosis (LAM)
Hospital Universitari de Bellvitge
Servicio de Neumología
HISZPANIA
Cataluña
L'HOSPITALET DE LLOBREGAT
IMPALA-2: Ensayo clínico aleatorizado, en doble ciego y controlado con placebo, de la administración de molgramostim, en solución para inhalación por nebulizador, una vez al día, en sujetos adultos con proteinosis alveolar pulmonar autoinmunitaria -ES
Hospital Universitari de Bellvitge
Servicio de Neumología
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
SEAL: Ensayo fase IIa/b, multicéntrico, aleatorizado, controlado con placebo y doble ciego, para evaluar la seguridad y la eficacia de adrenomedulina pegilada inhalada (PEG-ADM), en pacientes con Síndrome de distrés respiratorio agudo (SDRA)
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
The TRISTARDS Trial - ThRombolysIS Therapy for ARDS: Ensayo en fase IIb/III, operacionalmente óptimo, abierto, aleatorizado, secuencial, de grupos paralelos, adaptativo para evaluar la eficacia y la seguridad del tratamiento con alteplasa intravenosa diaria administrado hasta 5 días [...] en pacientes con síndrome de dificultad respiratoria aguda (SDRA) desencadenado por COVID-19
Institution: Information not provided - ES
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
Decision Support System to Evaluate VENTilation in ARDS (DeVENT)
Imperial College London, main campus
Imperial College London Headquarters
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Institution: Information not provided - US
AUSTRIA
STEIERMARK
GRAZ
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - AT
Medizinische Universität Graz
Klinische Abteilung für Pulmonologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-BASIS: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA) (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-X: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Etude de phase IIa multi-cohorte, randomisée, contrôlée par placebo, visant à évaluer la sécurité, la pharmacocinétique, la pharmacodynamique et l'activité clinique de doses croissantes de RXC007 chez des patients atteints de fibrose pulmonaire idiopathique - BE
Institution: Information not provided - BE
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
INTEGRIS-IPF : évaluation de phase 2a randomisée, en double aveugle, à dosage variable et contrôlée par placebo de l'innocuité, de la tolérabilité et de la pharmacocinétique du PLN-74809 chez des participants atteints de fibrose pulmonaire idiopathique - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de pneumologie
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STARSCAPE: Un essai de phase III randomisé, en double aveugle et contrôlé par placebo pour évaluer l'efficacité et l'innocuité du PRM-151 chez des patients atteints de fibrose pulmonaire idiopathique - BE
Erasme Hospital - ULB
Service de Pneumologie
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STARSCAPE-OLE: Une étude ouverte d'extension de phase III pour évaluer l'innocuité et l'efficacité à long terme du PRM-151 chez des patients atteints de fibrose pulmonaire idiopathique - BE
Erasme Hospital - ULB
Service de Pneumologie
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BI 1305-0014: Un essai en double aveugle, randomisé et contrôlé par placebo évaluant l'efficacité et l'innocuité du BI 1015550 sur 52 semaines chez des patients atteints de fibrose pulmonaire idiopathique
Erasme Hospital - ULB
Service de Pneumologie
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
Efficacy, Safety and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) in Children and Adolescent Subjects-CA
Institution: Information not provided - CA
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Etude roll-over de phase II, en ouvert, évaluant sur le long terme, l'efficacité, la tolérance et la sécurité du BIBF 1120 par voie orale chez les patients atteints de Fibrose Pulmonaire Idiopathique (FPI).
Institution: Information not provided - FR
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)-FR
Institution: Information not provided - FR
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 18 mg taken orally b.i.d. -FR
Institution: Information not provided - FR
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Etude de phase IIa multi-cohorte, randomisée, contrôlée par placebo, visant à évaluer la sécurité, la pharmacocinétique, la pharmacodynamique et l'activité clinique de doses croissantes de RXC007 chez des patients atteints de fibrose pulmonaire idiopathique -FR
Institution: Information not provided - FR
FRANCJA
GRAND-EST
NANCY
CURDYS: Utilisation d'un surfactant exogène chez des nouveau-nés grands prématurés présentant une détresse respiratoire sévère en prévention de la dysplasie bronchopulmonaire (phase IV)
CHU de Nancy - Maternité régionale
Maternite Regionale Universitaire - CHU Nancy
FRANCJA
ILE-DE-FRANCE
PARIS
EXCHANGE-IPF: Efficacité des échanges plasmatiques, du rituximab et des Immunoglobulines intraveineuses (IgIV) pour le traitement des exacerbations sévères de fibrose pulmonaire idiopathique hospitalisées en réanimation: un essai contrôlé randomisé ouvert.
CHU Paris Nord-Val de Seine - Hôpital Xavier Bichat-Claude Bernard
Service de pneumologie A
FRANCJA
ILE-DE-FRANCE
PARIS
EXAFIP : Intérêt du cyclophosphamide associé aux corticostéroïdes dans le traitement des excerbations aiguës de fibrose pulmonaire idiopathique : un essai randomisé contrôlé par placebo (Phase III)
Groupe hospitalier AP-HP.6 - Hôpital Tenon
Unité Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares
FRANCJA
ILE-DE-FRANCE
PARIS
Etude clinique de phase I/II, non-randomisée, monocentrique, en ouvert, évaluant l'injection de cellules autologues CD34+ transduites avec le vecteur lentiviral G1XCGD chez des patients atteints de Granulomatose Septique Chronique liée au chromosome X
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique
FRANCJA
ILE-DE-FRANCE
PARIS
Etude française d'extension en ouvert du canakinumab chez des patients souffrant d'arthrite juvénile idiopathique systémique (AJIs) ayant participé à l'étude internationale de phase III CACZ885G2301E1
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique - Rhumatologie
FRANCJA
NOUVELLE AQUITAINE
PESSAC
PIC'IRM : Apport de l'IRM thoracique dans la prise en charge de la fibrose pulmonaire idiopathique
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service de pneumologie
NIEMCY
Baden-Württemberg
HEIDELBERG
Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zur Bewertung der Sicherheit, Verträglichkeit, biologischen Aktivität und PK von ND-L02-s0201 bei Patienten mit idiopathischer Lungenfibrose (IPF)
Thoraxklinik-Heidelberg gGmbH
Abteilung für Pneumologie und Beatmungsmedizin
NIEMCY
Baden-Württemberg
HEIDELBERG
Eine randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie bei IPF-Patienten über 12 Wochen zur Bewertung der Wirksamkeit, Sicherheit und Verträglichkeit von BI 1015550 bei oraler Einnahme (Phase 2)
Thoraxklinik-Heidelberg gGmbH
Thoraxklinik Heidelberg
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
Langzeitsicherheitsstudie von Tofacinib bei Patienten mit jugendlicher idiopathischer Arthritis -DE-
Institution: Information not provided - DE
NIEMCY
Hamburg
HAMBURG
Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Schön Klinik Hamburg Eilbek
Hamburger Zentrum für Kinder- und Jugendrheumatologie
NIEMCY
Hessen
FRANKFURT AM MAIN
Gentherapie für X-CGD (X-CGD-Version2): Phase I/II somatische Gentherapiestudie zur Behandlung der X-chromosomalen septischen Granulomatose
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
NIEMCY
Hessen
FRANKFURT AM MAIN
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
NIEMCY
Hessen
GIEßEN
Einfluss von nicht-invasiver positiver Druckbeatmung versus nasaler Hochfrequenzoszillationsbeatmung auf Parameter der Oxygenierung und Ventilation bei Frühgeborenen in der Weaningphase nach Atemnotsyndrom
Kinderklinik des UKGM am Standort Gießen
Abteilung für Allgemeine Pädiatrie und Neonatologie
NIEMCY
Hessen
GIEßEN
Eine offene Verlängerungsstudie zur langfristigen Sicherheit von oralem BIBF 1120 bei Patienten mit idiopathischer Lungenfibrose (Phase III)
Med. Klinik und Poliklinik II des UKGM am Standort Gießen
Schwerpunkt Pneumologie und Intensivmedizin - Fibrosierende Lungenerkrankungen
NIEMCY
Hessen
GIEßEN
Zephyrus II: Eine randomisierte, doppelblinde, placebokontrollierte Wirksamkeits- und Sicherheitsstudie der Phase 3 mit Pamrevlumab bei Patienten mit idiopathischer Lungenfibrose (IPF)
Med. Klinik und Poliklinik II des UKGM am Standort Gießen
Schwerpunkt Pneumologie und Intensivmedizin - Fibrosierende Lungenerkrankungen
NIEMCY
Hessen
IMMENHAUSEN
Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zur Bewertung der Sicherheit, Verträglichkeit, biologischen Aktivität und PK von ND-L02-s0201 bei Patienten mit idiopathischer Lungenfibrose (IPF)
Lungenfachklinik Immenhausen
Zentrum für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin
NIEMCY
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie bei IPF-Patienten über 12 Wochen zur Bewertung der Wirksamkeit, Sicherheit und Verträglichkeit von BI 1015550 bei oraler Einnahme (Phase 2)
Universitätsklinikum Essen
NIEMCY
Nordrhein-Westfalen
ESSEN
Eine multizentrische, offene einarmige Studie zur Untersuchung der Sicherheit und Verträglichkeit von Pirfenidone (Esbriet) in Kombination mit Nintedanib (Ofev) bei Patienten mit Idiopathischer Lungenfibrose (Phase IV)
Universitätsmedizin Essen - Ruhrlandklinik
Abteilung für Interventionelle Pneumologie
NIEMCY
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zur Bewertung der Sicherheit, Verträglichkeit, biologischen Aktivität und PK von ND-L02-s0201 bei Patienten mit idiopathischer Lungenfibrose (IPF)
Universitätsmedizin Essen - Ruhrlandklinik
Klinik für Pneumologie
NIEMCY
Nordrhein-Westfalen
ESSEN
Zephyrus II: Eine randomisierte, doppelblinde, placebokontrollierte Wirksamkeits- und Sicherheitsstudie der Phase 3 mit Pamrevlumab bei Patienten mit idiopathischer Lungenfibrose (IPF)
Universitätsmedizin Essen - Ruhrlandklinik
Klinik für Pneumologie
NIEMCY
Nordrhein-Westfalen
MÜNSTER
Eine randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie bei IPF-Patienten über 12 Wochen zur Bewertung der Wirksamkeit, Sicherheit und Verträglichkeit von BI 1015550 bei oraler Einnahme (Phase 2)
Universitätsklinikum Münster
NIEMCY
Nordrhein-Westfalen
SANKT AUGUSTIN
Eine multizentrische, offene Studie zur Untersuchung der Pharmakokinetik, Sicherheit und Pharmakodynamik von subkutan verabreichtem Belimumab, einem humanen monoklonalen Anti-BLyS-Antikörper, plus Standardtherapie bei pädiatrischen Teilnehmern mit systemischem Lupus erythematodes (SLE) (Phase II)
Asklepios Kinderklinik Sankt Augustin GmbH
Abteilung für Allgemeine Kinder- und Jugendmedizin
IRLANDIA
County Dublin
DUBLIN
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis - IE
St. Vincent's University Hospital
CF Clinic
WŁOCHY
TOSCANA
FIRENZE
Studio randomizzato, in aperto, multinazionale, multicentrico, suddiviso in due parti nei neonati pretermine con respirazione spontanea con Sindrome da Distress respiratorio da lieve a moderata, volta a valutare la sicurezza, la tollerabilità e l'efficacia di Poractant Alfa (Surfattante porcino, Curosurf®) in confronto con la sola nCPAP
Azienda Ospedaliero Universitaria Careggi
S.O.D. Neonatologia e Terapia Intensiva Neonatale
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis
Institution: Information not provided - JP
HOLANDIA
Gelderland
NIJMEGEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
CWZ - Canisius Wilhelmina Ziekenhuis
HOLANDIA
Limburg
HEERLEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
Zuyderland Medisch Centrum, locatie Heerlen
HOLANDIA
Noord-Brabant
EINDHOVEN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
Catharina Ziekenhuis
HOLANDIA
Noord-Holland
AMSTERDAM
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
Amsterdam UMC, locatie VUmc
HOLANDIA
Utrecht
NIEUWEGEIN
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
St. Antonius Ziekenhuis
HOLANDIA
Utrecht
UTRECHT
Gastrointestinal side effects of MTX in patients with JIA: Phase III effectiveness multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate (MTX) related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus standard of care
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HOLANDIA
Zuid-Holland
LEIDEN
BeSt for kids: een gerandomizeerde klinische interventiestudie om de effecten van verschillende behandelingsstrategieën te testen in patiënten met jeugdreuma (JIA)
LUMC - Leids Universitair Medisch Centrum
Willem-Alexander Kinderziekenhuis
PORTUGALIA
SUL
LISBOA
A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis - PT
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria
Serviço de Pneumologia
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
ELIKIDS: Estudio abierto, de dos cohortes (con y sin imiglucerasa) y multicéntrico para evaluar la farmacocinética (FC), seguridad y eficacia de eliglustat en pacientes pediátricos con enfermedad de Gaucher (EG) tipo 1 (EG1) y tipo 3 (EG3)
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio multicéntrico, abierto para evaluar la farmacocinética, seguridad y farmacodinamia de belimumab en administración subcutánea, un anticuerpo monoclonal anti-BLyS humano, añadido al tratamiento estándar en participantes pediátricos con lupus eritematoso sistémico (LES)
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio abierto de seguimiento a largo plazo de tofacitinib para el tratamiento de la artritis idiopática juvenil (AIJ) - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
JUVE-X: Estudio de fase 3, multicéntrico, en el que se evalúan la seguridad y la eficacia a largo plazo de baricitinib en pacientes de entre 1 y menos de 18 años con artritis idiopática juvenil (AIJ)
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
PROTECT: Estudio aleatorizado, multicéntrico, doble ciego, de grupos paralelos y controlado con principio activo, de la eficacia y la seguridad de esparsentán para el tratamiento de la nefropatía por inmunoglobulina A -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
NefIgArd: Estudio randomizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de Nefecon en pacientes con nefropatía por IgA primaria en riesgo de progresión a enfermedad renal terminal - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 2, aleatorizado, doble ciego y controlado con placebo de cemdisirán en pacientes adultos con nefropatía por IgA - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio aleatorizado, con doble enmascaramiento, controlado con placebo y de grupos paralelos en pacientes con FPI para evaluar la eficacia, seguridad y tolerabilidad a lo largo de 12 semanas de 18 mg BI 1015550 administrados por vía oral dos veces al día - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
GALACTIC-1: Estudio de fase IIb, aleatorizado, doble ciego, multicéntrico, con grupos paralelos, controlado con placebo en pacientes con fibrosis pulmonar idiopática (FPI) para investigar la eficacia y la seguridad de TD139, un inhibidor de la galectina-3 inhalado administrado mediante un inhalador de polvo seco durante 52 semanas - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Ensayo de fase III, aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y seguridad del PRM-151 en pacientes con fibrosis pulmonar idiopática - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo y de dosis múltiples para evaluar la eficacia y la seguridad de VIS649 en participantes con nefropatía por inmunoglobulina A (IgA) (NIgA) - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Zephyrus II: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, de eficacia y seguridad de pamrevlumab en sujetos con fibrosis pulmonar idiopática (FPI)
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
ARTEMIS - IGAN: Estudio en fase 3, aleatorizado, doble ciego, controlado con placebo de la seguridad y eficacia de OMS721 en pacientes con nefropatía por inmunoglobulina A (IgA)
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio fase 2 multicéntrico, aleatorizado, doble ciego, controlado con placebo de la eficacia, seguridad y tolerabilidad de BMS-986278 en pacientes con fibrosis pulmonar
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
RENEW: Estudio abierto, de seguridad, tolerabilidad, y prueba de concepto con la terapia oral BCX9930 en sujetos con glomerulopatía C3, nefropatía por inmunoglobulina A, o nefropatía membranosa primaria
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
EPPIK: Estudio de cohortes de fase 2, con un solo grupo, abierto para evaluar la seguridad, la eficacia y la farmacocinética del tratamiento con esparsentán en pacientes pediátricos con determinadas enfermedades glomerulares proteinúricas
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ravulizumab en participantes adultos con microangiopatía trombótica asociada a un desencadenante
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
STARSCAPE-OLE: Estudio de extensión de etiqueta abierta de fase III para evaluar la seguridad y eficacia a largo plazo del PRM-151 en pacientes con fibrosis pulmonar idiopática (FPI)
Institution: Information not provided - ES
SZWECJA
Region Stockholm
HUDDINGE
SAINT - Surfactant Administration by Insure or Thin Catheter - SE
Karolinska Institutet
Department of Clinical Science, Intervention and Technology (CLINTEC)
SZWAJCARIA
Suisse Alémanique
ZÜRICH
Surfactant Nebulization for the Early Aeration of the Preterm Lung: a Single Blinded, Parallel, Randomized Controlled Trial
Universitätspital Zürich
Klinik für Neonatologie
SZWAJCARIA
Suisse Alémanique
ZÜRICH
The FUNK-FLOW Study - Functional Residual Capacity During Different Levels of High-flow in Preterm Infants
Universitätspital Zürich
Klinik für Neonatologie
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFN?) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary HLH(MAS/sHLH)-GB
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Cambridgeshire
CAMBRIDGE
Biologics in refractory vasculitis
University of Cambridge
Department of Medicine
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis -GB
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
IPF-COMFORT: A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis -GB
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit
ZJEDNOCZONE KRÓLESTWO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
ATLAS Study: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis -GB
Institution: Information not provided - UK
ZJEDNOCZONE KRÓLESTWO
Nottinghamshire
NOTTINGHAM
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)GB
LAM Action Nottingham, Voluntary Action Centre
Division of Respiratory Medicine, Clinical Sciences Building
STANY ZJEDNOCZONE AMERYKI
Michigan
DETROIT
Aerosolized Survanta in Neonatal Respiratory Distress Syndrome: Phase I/II Study - US
Wayne State University
STANY ZJEDNOCZONE AMERYKI
Texas
DALLAS
LEAP: A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 (Phase II) - US
Baylor University Medical Center
Institute of Metabolic Disease
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
ARAMIS: A Randomized Multicenter Study for Isolated Skin Vasculitis
Institution: Information not provided - US
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -AU
Institution: Information not provided - AU
AUSTRIA
STEIERMARK
GRAZ
ANCA_CGM: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis (phase 4)
Medizinische Universität Graz
Klinische Abteilung für Nephrologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
JUVE-BALM: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthritis (sJIA) (Phase 3) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PEAPOD: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis - AT
Institution: Information not provided - AT
BELGIA
OOST-VLAANDEREN
GENT
Multicenter, open-label, werkzaamheids-, veiligheid-, verdraagbaarheids- en farmacokinetische studie van subcutaan Ixekizumab met Adalimumab-referentie-arm, bij kinderen met juveniele idiopathische artritis subtypes van enthesitis-gerelateerde artritis (inclusief juveniele spondylitis ankylopoetica) en juveniele psoriatische artritis - BE
Ghent University Hospital - UZ Gent
Reumatologie kinderen
BELGIA
VLAAMS BRABANT
LEUVEN
Een langetermijnonderzoek om de voortdurende veiligheid en werkzaamheid van recombinant humaan zuur-sfingomyelinase te beoordelen bij patiënten met zure sfingomyelinase-deficiëntie - BE
UZ Leuven - Campus Gasthuisberg
Centrum metabole ziekten - UZ Leuven
BELGIA
VLAAMS BRABANT
LEUVEN
EMERALD : Een twee-cohort, open-label, eenarmige, multicenter studie om de werkzaamheid, veiligheid en verdraagbaarheid, PK en PD, van emapalumab te evalueren bij kinderen en volwassenen met MAS bij de ziekte van Still of met MAS bij systemische lupus erythemateuze - BE
UZ Leuven - Campus Gasthuisberg
Reference Centre for Rare Immune Deficiency, Autoimmune and Autoinflammatory Diseases - UZ Leuven
BUŁGARIA
South-West region
SOFIA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - BG -
University Hospital Alexandrovska
Clinic of Hematology
CZECHY
Capital City Prague
PRAHA
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - CZ -
Vseobecna fakultni nemocnice a 1. lekarska fakulta UK
National Centre for Treatment of Gaucher Disease
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
MASTER-ANCA: Etude prospective multicentrique randomisée comparant l'arrêt ou la poursuite du traitement immunosuppresseur d'entretien des vascularites associées aux ANCA chez les patients en Insuffisance Rénale Terminale.
Institution: Information not provided - FR
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis -FR
Institution: Information not provided - FR
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
UNITED : étude de phase 3, multicentrique, en ouvert, d'extension à long terme de l'ustekinumab chez les participants inclus dans les études cliniques pédiatriques (âgés de 2 à <18 ans) -FR
Institution: Information not provided - FR
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EMERALD : étude multicentrique à deux cohortes, en ouvert, bras unique, visant à évaluer l'efficacité, l'innocuité et la tolérance, la pharmacocinétique et la pharmacodynamique, d'émapalumab chez les enfants et les adultes atteints de SAM dans la maladie de Still ou de SAM dans le lupus érythémateux systémique -FR
Institution: Information not provided - FR
FRANCJA
ILE-DE-FRANCE
CLICHY
ENCORE : Étude de phase 3, randomisée, multicentrique, internationale, en ouvert, avec comparateur actif, visant à évaluer l'efficacité et la tolérance de Genz-112638, chez des patients atteints de la maladie de Gaucher de type 1, ayant atteint les objectifs thérapeutiques avec un traitement enzymatique de substitution.
CHU Paris Nord-Val de Seine - Hôpital Beaujon
Service de médecine interne
FRANCJA
ILE-DE-FRANCE
LE KREMLIN-BICÊTRE
Etude d'extension à long terme de l'efficacité et de la tolérance du tocilizumab sous cutané chez les patients atteints d'AJI systémiques et polyarticulaires actives (Phase I) - FR
APHP. Université Paris-Saclay, Hôpital Bicêtre
Service de Rhumatologie pédiatrique
FRANCJA
ILE-DE-FRANCE
PARIS
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) - FR
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
FRANCJA
ILE-DE-FRANCE
PARIS
AJIBIOREM : Décroissance thérapeutique dans l'arthrite juvénile idiopathique oligoarticulaire ou polyarticulaire sans facteur rhumatoïde en maladie inactive sous biothérapie (Phase III)
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique - Rhumatologie
FRANCJA
ILE-DE-FRANCE
PARIS
Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial - FR
Hôpital Necker-Enfants Malades
Service de Génétique Moléculaire
NIEMCY
Baden-Württemberg
FREIBURG
Multizentrische, offene Studie zur Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von subkutanem Ixekizumab mit Adalimumab-Referenzarm bei Kindern mit juveniler idiopathischer Arthritis, Subtypen von Enthesitis-bezogener Arthritis (einschließlich juveniler ankylosierender Spondylitis) und juveniler Psoriasis-Arthritis
Zentrum für Kinder- und Jugendmedizin Freiburg
Sektion für Pädiatrische Infektiologie und Rheumatologie der Klinik für Allgemeine Kinder- und Jugendmedizin
NIEMCY
Bayern
GARMISCH-PARTENKIRCHEN
ß-SPECIFIC 4 Patients: Eine offene Studie zur Beurteilung der Wirksamkeit und Sicherheit von Canakinumab (wenn die Dosis reduziert wird oder das Dosisintervall verlängert wird) bei Patienten mit systemischer juveniler idiopathischer Arthritis (Phase III) - DE
Kinderklinik Garmisch-Partenkirchen gGmbH
Deutsches Zentrum für Kinder- und Jugendrheumatologie
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
Langfristige Verlängerungsstudie zur Beurteilung der Sicherheit und Wirksamkeit von subkutanem Tocilizumab bei Patienten mit polyartikulär verlaufender und systemischer juveniler idiopathischer Arthritis.
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
Eine offene, sequentielle, aufsteigende, wiederholte Dosisfindungsstudie von Sarilumab, verabreicht mit subkutaner (SC) Injektion, bei Kindern und Jugendlichen im Alter von 2 bis 17 Jahren, mit Polyartikulärer Juveniler Idiopathischer Arthritis (pcJIA), gefolgt von einer Verlängerungsphase (Phase II).
Institution: Information not provided - DE
NIEMCY
Berlin
BERLIN
Multizentrische, offene Studie zur Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von subkutanem Ixekizumab mit Adalimumab-Referenzarm bei Kindern mit juveniler idiopathischer Arthritis, Subtypen von Enthesitis-bezogener Arthritis (einschließlich juveniler ankylosierender Spondylitis) und juveniler Psoriasis-Arthritis
Deutsches Rheuma-Forschungszentrum Berlin
Forschungsbereich Epidemiologie
NIEMCY
Berlin
BERLIN
Multizentrische, offene Studie zur Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von subkutanem Ixekizumab mit Adalimumab-Referenzarm bei Kindern mit juveniler idiopathischer Arthritis, Subtypen von Enthesitis-bezogener Arthritis (einschließlich juveniler ankylosierender Spondylitis) und juveniler Psoriasis-Arthritis
HELIOS Klinikum Berlin-Buch
Klinik für Kinder- und Jugendmedizin
NIEMCY
Bremen
BREMEN
Multizentrische, offene Studie zur Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von subkutanem Ixekizumab mit Adalimumab-Referenzarm bei Kindern mit juveniler idiopathischer Arthritis, Subtypen von Enthesitis-bezogener Arthritis (einschließlich juveniler ankylosierender Spondylitis) und juveniler Psoriasis-Arthritis
Klinikum Bremen-Mitte
Eltern-Kind-Zentrum Prof. Hess
NIEMCY
Hamburg
HAMBURG
Multizentrische, offene Studie zur Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von subkutanem Ixekizumab mit Adalimumab-Referenzarm bei Kindern mit juveniler idiopathischer Arthritis, Subtypen von Enthesitis-bezogener Arthritis (einschließlich juveniler ankylosierender Spondylitis) und juveniler Psoriasis-Arthritis
Schön Klinik Hamburg Eilbek
Hamburger Zentrum für Kinder- und Jugendrheumatologie
NIEMCY
Nordrhein-Westfalen
SANKT AUGUSTIN
Multizentrische, offene Studie zur Wirksamkeit, Sicherheit, Verträglichkeit und Pharmakokinetik von subkutanem Ixekizumab mit Adalimumab-Referenzarm bei Kindern mit juveniler idiopathischer Arthritis, Subtypen von Enthesitis-bezogener Arthritis (einschließlich juveniler ankylosierender Spondylitis) und juveniler Psoriasis-Arthritis
Asklepios Kinderklinik Sankt Augustin GmbH
Abteilung für Allgemeine Kinder- und Jugendmedizin
NIEMCY
Rheinland-Pfalz
MAINZ
ASCEND: Eine multizentrische , randomisierte, doppelblinde , Placebo-kontrollierte Phase 2/3-Wiederholungsdosis-Studie zur Untersuchung der Wirksamkeit, Sicherheit, Pharmakodynamik und Pharmakokinetik von Olipudase alfa bei Patienten mit Säure-Sphingomyelinase-Mangel
Universitätsmedizin Mainz
Villa Metabolica - Schwerpunktbereich angeborene Stoffwechselerkrankungen
IZRAEL
ISRAEL
PETAH TIKVA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - IL -
Rabin Medical Center - Beilinson Hospital
Recanati Genetic Institute
WŁOCHY
CAMPANIA
NAPOLI
Valutazione dell'efficacia e del trattamento con Miglustat in pazienti affetti da malattia di Niemann-Pick di tipo c
Azienda Ospedaliera Universitaria "Federico II"
Laboratorio Dipartimento di Pediatria
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio in aperto suddiviso in due parti per valutare il beneficio clinico e la sicurezza a lungo termine di Etanercept in bambini e adolescenti affetti da artrite idiopatica giovanile nella forma oligoarticolare estesa, artrite associata ad entesite o artrite psoriasica - IT
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di fase III di 'withdrawal', randomizzato, in doppio cieco, placebo controllato, di 24 settimane preceduto da una fase iniziale in aperto di 16 settimane e seguito da un follow-up in aperto di 64 settimane, per valutare l' efficacia e la sicurezza di tocilizumab in pazienti affetti da artrite idiopatica giovanile attiva a corso poliarticolare - IT
Institution: Information not provided - IT
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di estensione a lungo termine per valutare la sicurezza e l'efficacia di Tocilizumab sottocutaneo in pazienti con decorso poliarticolare e artrite idiopatica giovanile sistemica - IT
Institution: Information not provided - IT
WŁOCHY
FRIULI VENEZIA GIULIA
UDINE
ENCORE : Studio di fase 3, multicentrico nazionale, open-label, randomizzato per valutare l'efficacia e la sicurezza di Genz-112638 in pazienti con patologia di Gaucher tipo 1 trattati con terapia enzimatica sostitutiva.
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Centro di Coordinamento Regionale per le Malattie Rare
WŁOCHY
PUGLIA
BARI
Terapia combinata della crioglobulinemia mista HCV-correlata con Interferone-alpha pegilato, ribavirina e rituximab
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica
LIBAN
Beyrouth
BEIRUT
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - LB -
Hôtel-Dieu de France, Université Saint-Joseph
Oncology & Hematology
HOLANDIA
Noord-Holland
AMSTERDAM
ASCEND: A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency - NL
Amsterdam UMC, locatie AMC
Afdeling Erfelijke Stofwisselingsziekten
HOLANDIA
Utrecht
UTRECHT
B-Vit in JIA: Beïnvloeden van regulatoire Tcel functie in JIA met Vitamine B3 (nicotinamide) behandeling
UMC Utrecht - Universitair Medisch Centrum Utrecht
Kinderreumacentrum
HOLANDIA
Utrecht
UTRECHT
VAART studie: mulicenter gerandomiseerde klinische interventiestudie in patiënten met jeugdreuma (JIA) - veiligheid en efficiency van vaccinatie met levend afgezwakt gecombineerd vaccin voor mazelen-bof-rubella
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HOLANDIA
Utrecht
UTRECHT
A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HOLANDIA
Utrecht
UTRECHT
CLIPPER2: An Open-label Extension Study to Assess the Long-term Safety and Clinical Benefit of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled in Protocol 0881A1-3338-ww (Phase II-III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HOLANDIA
Utrecht
UTRECHT
Beta-SPECIFIC 3: An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HOLANDIA
Utrecht
UTRECHT
Beta-SPECIFIC 4Pa: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HOLANDIA
Utrecht
UTRECHT
ESTIS trial: Biomarker-gestuurde behandelstrategie voor anakinra in systemische Juveniele Idiopathische Arthritis
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HOLANDIA
Zuid-Holland
LEIDEN
CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiopathic Arthritis (Phase IV).
LUMC - Leids Universitair Medisch Centrum
Willem-Alexander Kinderziekenhuis
SŁOWACJA
Bratislavsky kraj
ADDRESS: NOT PROVIDED - SK
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -SK
Institution: Information not provided - SK
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de sarilumab administrado con inyección subcutánea (s. c.) a niños y adolescentes con edades comprendidas entre 2 y 17 años con artritis idiopática juvenil de curso poliarticular (AIJP), seguido de una fase de extensión - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Eficacia, seguridad, tolerabilidad y farmacocinética de tofacitinib para el tratamiento de la artritis idiopática juvenil sistémica (aijs) con características sistémicas activas en niños y adolescentes - ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
JUVE-BRIGHT: Estudio sin enmascaramiento, comparativo con un tratamiento activo, en el que se evalúan la seguridad y la eficacia del tratamiento con baricitinib por vía oral en pacientes de entre 2 y menos de 18 años que presentan uveítis asociada con artritis idiopática juvenil activa o uveítis anterior crónica y anticuerpos antinucleares -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio multicéntrico, sin enmascaramiento, con un grupo de referencia con adalimumab, para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de ixekizumab por vía subcutánea en niños con los subtipos de artritis idiopática juvenil: artritis relacionada con entesitis (incluida la espondilitis anquilosante de aparición durante la infancia) y artritis psoriásica juvenil
Institution: Information not provided - ES
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
EMERALD: Estudio abierto, multicéntrico, de dos cohortes y un solo grupo para evaluar [...] emapalumab en niños y adultos con síndrome de activación de macrófagos (SAM) en la enfermedad de Still (incluida la artritis idiopática juvenil sistémica y la enfermedad de Still del adulto) o con SAM en el lupus eritematoso sistémico -ES
Institution: Information not provided - ES
HISZPANIA
Madrid
MADRID
ASCEND: Estudio en fase II/III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, con dosis repetidas y de comparación de dosis para evaluar la eficacia, seguridad, farmacodinámica y farmacocinética de olipudasa alfa en pacientes con deficiencia de esfingomielinasa ácida
Hospital Universitario Ramón y Cajal
Servicio de Hematología y Hemoterapia
SZWECJA
Region Stockholm
ADDRESS: NOT PROVIDED - SE
EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous - SE
Institution: Information not provided - SE
SZWAJCARIA
Suisse Alémanique
BERN
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - CH
Universitätsspital Inselspital
University Hospital Inselspital
TUNEZJA
TUNISIA
TUNIS
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - TN -
Hôpital La Rabta
Service de Pédiatrie
TURCJA
TURKEY
IZMIR
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - TR -
Ege Üniversitesi
Department of Pediatrics - Cocuk asgligi ve Hastaliklari Anabilim Dali
ZJEDNOCZONE KRÓLESTWO
Cambridgeshire
CAMBRIDGE
Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
Addenbrooke's Hospital
Addenbrookes Hospital
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -GB
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
A Long-Term Study to Assess the Ongoing Safety and Efficacy of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency - UK
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College London, main campus
Imperial College London Headquarters
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College NHS Trust
ZJEDNOCZONE KRÓLESTWO
Merseyside
LIVERPOOL
STANY ZJEDNOCZONE AMERYKI
Georgia
ATLANTA
STANY ZJEDNOCZONE AMERYKI
New York
NEW YORK
ASCEND-Peds: A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency - US
Icahn School of Medicine at Mount Sinai
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications
Institution: Information not provided - US
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Programme d'accès à long terme au mépolizumab pour les sujets ayant participé à l'étude MEA115921 (étude du mépolizumab dans le traitement de la granulomatose éosinophilique avec polyangéite chez des sujets recevant un traitement de référence) - FR
Institution: Information not provided - FR
FRANCJA
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
MAINEPSAN: Etude prospective, multicentrique, contrôlée, randomisée, évaluant une administration prolongée de prednisone en traitement d'entretien dans les vascularites systémiques associées aux ANCA.
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire
FRANCJA
ILE-DE-FRANCE
PARIS
CHUSPAN2 : Evaluation d'une nouvelle stratégie de traitement de patients atteints de polyangéite microscopique, périartérite noueuse ou syndrome de Churg-Strauss sans facteur de pronostic défavorable (Phase III)
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
NIEMCY
Baden-Württemberg
MANNHEIM
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Langzeitzugangsprogramm für Probanden, die an der Studie MEA115921 (Placebo-kontrollierte Studie von Mepolizumab zur Behandlung von eosinophiler Granulomatose mit Polyangiitis bei Probanden mit Standardtherapie) teilgenommen haben. - DE-
Institution: Information not provided - DE
NIEMCY
Berlin
BERLIN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Charité - Universitätsmedizin Berlin
NIEMCY
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Essen
NIEMCY
Nordrhein-Westfalen
MÜNSTER
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Münster
NIEMCY
Sachsen
DRESDEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
NIEMCY
Thüringen
JENA
HOLANDIA
Groningen
GRONINGEN
Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie
HOLANDIA
Utrecht
UTRECHT
GO KIDS: A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy (Phase III) - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Immunologie
HISZPANIA
Cataluña
BARCELONA
ABROGATE: Abatacept (CTLA4-Ig) para el tratamiento de la recaída no grave de granulomatosis con poliangeítis (Wegener)
Hospital Clínic de Barcelona
HISZPANIA
Madrid
ADDRESS: NOT PROVIDED - ES
OCEAN: Un estudio de 52 semanas, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad para investigar la eficacia y seguridad de depemokimab en comparación con mepolizumab en adultos con granulomatosis eosinofílica con poliangeítis (EGPA, por sus siglas en inglés) recidivante o refractaria que reciben el tratamiento habitual -ES
Institution: Information not provided - ES
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Institution: Information not provided - US
Wieloośrodkowe badania kliniczne
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care.
King's College London
King's College London Headquarters
DANIA
Jylland
ADDRESS: NOT PROVIDED - DK
A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients IMPALA
Institution: Information not provided - DK
DANIA
Jylland
ADDRESS: NOT PROVIDED - DK
IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients
Institution: Information not provided - DK
JAPONIA
JAPAN
ADDRESS : NOT PROVIDED - JP
IMPALA-2: A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP)
Institution: Information not provided - JP
SZWAJCARIA
Suisse Alémanique
BASEL
EXIST-2: Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Novartis International AG
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (Everolimus) in patients with lymphangioleiomyomatosis (Phase II)
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome)
Imperial College London, main campus
Imperial College London Headquarters
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis
Institution: Information not provided - US
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
A multi-centre, randomised, controlled, non-inferiority trial in preterm infants with respiratory distress syndrome, comparing surfactant administration by supraglottic airway with minimally invasive surfactant therapy, assessing need for mechanical ventilation or repeat surfactant therapy within 72 hours of randomisation.
Institution: Information not provided - AU
BELGIA
VLAAMS BRABANT
MECHELEN
FINLANDIA
Finland
ADDRESS : NOT PROVIDED - FI
A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 18 mg taken orally b.i.d.
Institution : Information not provided - FI
FRANCJA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (Phase I-II) (Coordination)
Institution: Information not provided - FR
FRANCJA
ILE-DE-FRANCE
EVRY
NET4CGD: Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)
Généthon
Centre de Recherche Généthon
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (Phase III) (Coordination)
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) (Phase III)
Institution: Information not provided - DE
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)
Institution: Information not provided - DE
NIEMCY
Rheinland-Pfalz
INGELHEIM AM RHEIN
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF) (Phase III) coordination
Boehringer Ingelheim Pharma GmbH & Co. KG
Boehringer Ingelheim Pharma GmbH
WŁOCHY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone
Institution: Information not provided - IT
HOLANDIA
Utrecht
ADDRESS: NOT PROVIDED - NL
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (Phase III) (Coordination)
Institution: Information not provided - NL
HOLANDIA
Utrecht
ADDRESS: NOT PROVIDED - NL
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Institution: Information not provided - NL
SZWAJCARIA
Suisse Alémanique
ALLSCHWIL
MUSIC: A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis (Phase II) (coordination)
Actelion Pharmaceuticals Ltd.
SZWAJCARIA
Suisse Alémanique
ALLSCHWIL
BUILD 3 - Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter double-blind randomized placebo-controlled, parallel group, event-driven, group sequential, phase III study (coordination)
Actelion Pharmaceuticals Ltd.
SZWAJCARIA
Suisse Alémanique
BASEL
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Group 3 Pulmonary Hypertension
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Institution: Information not provided - CH
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFN?) monoclonal antibody, in patients with systemic Juvenile Idiopathic Arthritis (sJIA) developing Macrophage Activation Syndrome/secondary HLH(MAS/sHLH)
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Essex
HARLOW
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants with Systemic Lupus Erythematosus (SLE)
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Limited
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
SPIRIT: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
ATLAS Study: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis.
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
LONDON
IPF-COMFORT: A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis.
King's College Hospital
Department of Respiratory Medicine
STANY ZJEDNOCZONE AMERYKI
Massachusetts
CAMBRIDGE
STANY ZJEDNOCZONE AMERYKI
New York
NEW YORK
STANY ZJEDNOCZONE AMERYKI
New York
NEW YORK
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis (Phase II-III)
Pfizer, Inc.
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
An Open-label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Cp-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (Jia)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Long-Term, Open-Label Follow-Up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (JIA)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) In Children And Adolescent Subjects
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Safety of Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis in Adults with no Treatment Alternatives
Institution: Information not provided - US
KANADA
Alberta
MOUNTAIN VIEW
NIEMCY
Berlin
ADDRESS: NOT PROVIDED - DE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (Phase III) (terminated)
Institution: Information not provided - DE
HOLANDIA
Noord-Holland
NAARDEN
HOLANDIA
Utrecht
ADDRESS: NOT PROVIDED - NL
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Institution: Information not provided - NL
HOLANDIA
Zuid-Holland
LEIDEN
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis
LUMC - Leids Universitair Medisch Centrum
SZWAJCARIA
Suisse Alémanique
BASEL
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab (Phase III) - coordination
Institution: Information not provided - CH
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
ß-SPECIFIC 4 Patients: An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) (Phase III)
Institution: Information not provided - CH
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase I Pharmacokinetic and Safety Study of Tocilizumab (TCZ) in Patients Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
Institution: Information not provided - CH
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A phase Ib, open-label, multicenter study to investigate the pharmacokinetics, pharmacodynamics, and safety of tocilizumab following subcutaneous administration to patients with systemic juvenile idiopathic arthritis
Institution: Information not provided - CH
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous.
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
CLIPPER2: An Open-label Extension Study to Assess the Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled in Protocol 0881A1-3338-ww (Phase II-III) (Coordination)
Institution: Information not provided - UK
ZJEDNOCZONE KRÓLESTWO
Oxfordshire
BEGBROKE
STANY ZJEDNOCZONE AMERYKI
Massachusetts
CAMBRIDGE
STANY ZJEDNOCZONE AMERYKI
New Jersey
RARITAN
UNITED: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age).
Janssen Research & Development, LLC
Janssen Research & Development, LLC.
STANY ZJEDNOCZONE AMERYKI
Pennsylvania
PHILADELPHIA
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) (coordination)
Hospital of the University of Pennsylvania
Rheumatology Division
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
Institution: Information not provided - US
STANY ZJEDNOCZONE AMERYKI
Washington
ADDRESS: NOT PROVIDED - US
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Institution: Information not provided - US
SZWAJCARIA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A phase IIa, international, multicentre, open-label, uncontrolled study to evaluate the safety and pharmacokinetics of 4× 375 mg/m2 intravenous rituximab in paediatric patients with severe granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis
Institution: Information not provided - CH
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB
A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy (Phase III)
Institution: Information not provided - GB
ZJEDNOCZONE KRÓLESTWO
Greater London
ADDRESS: NOT PROVIDED - GB